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Abstract
The membrane proximal external region (MPER) of HIV-1 gp41 has several features that make it an attractive antibody-
based vaccine target, but eliciting an effective gp41 MPER-specific protective antibody response remains elusive. One
fundamental issue is whether the failure to make gp41 MPER-specific broadly neutralizing antibodies like 2F5 and 4E10 is
due to structural constraints with the gp41 MPER, or alternatively, if gp41 MPER epitope-specific B cells are lost to
immunological tolerance. An equally important question is how B cells interact with, and respond to, the gp41 MPER
epitope, including whether they engage this epitope in a non-canonical manner i.e., by non-paratopic recognition via B cell
receptors (BCR). To begin understanding how B cells engage the gp41 MPER, we characterized B cell-gp41 MPER
interactions in BALB/c and C57BL/6 mice. Surprisingly, we found that a significant (,7%) fraction of splenic B cells from
BALB/c, but not C57BL/6 mice, bound the gp41 MPER via their BCRs. This strain-specific binding was concentrated in IgM
hi
subsets, including marginal zone and peritoneal B1 B cells, and correlated with enriched fractions (,15%) of gp41 MPER-
specific IgM secreted by in vitro-activated splenic B cells. Analysis of Igh
a (BALB/c) and Igh
b (C57BL/6) congenic mice
demonstrated that gp41 MPER binding was controlled by determinants of the Igh
a locus. Mapping of MPER gp41
interactions with IgM
a identified MPER residues distinct from those to which mAb 2F5 binds and demonstrated the
requirement of Fc CH regions. Importantly, gp41 MPER ligation produced detectable BCR-proximal signaling events,
suggesting that interactions between gp41 MPER and IgM
a determinants may elicit partial B cell activation. These data
suggest that low avidity, non-paratopic interactions between the gp41 MPER and membrane Ig on naı ¨ve B cells may
interfere with or divert bnAb responses.
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Introduction
A major roadblock in generating an effective HIV-1 vaccine has
been the inability to elicit broadly neutralizing antibodies (bnAbs),
capable of neutralizing a diverse variety of HIV-1 primary isolates,
either during acute HIV-1 infections, or after immunization with
various HIV-1 envelope (Env) immunogens [1–4]. Explanations
for the poor immunogenicity of HIV-1 Env include the emergence
of a glycan shield covering large portions of gp120 [5–8],
conformational shifting [5,9], and the high mutation rates of
HIV-1 Env structural genes [7,10]. Significant advances in
studying the capacity of humans to make protective Ab include
the isolation of rare human bnAbs isolated from HIV-1 infected
patients, such as 2F5, 4E10, 2G12, 1b12 and Z13, and the
characterization of their interactions with various regions of the
HIV Env [11]. Passive infusion of mixtures of 2F5, 4E10, 1b12 or
2G12 into rhesus monkeys protects against SHIV infection,
providing hope that if these antibodies could be induced in man, a
preventive HIV-1 vaccine might be possible [12,13].
Two of these rare bnAbs, 2F5 and 4E10, interact with a
particularly attractive target for a B cell-based HIV-1 vaccine, the
HIV-1 gp41 membrane proximal external region (MPER), in the
neighboring linear, neutralizing core epitopes ELDKWA and
NWFDIT, respectively [2,14–22]. Although immunization with
Env subunit immunogens containing gp41 MPER core epitopes
can elicit non-neutralizing gp41 MPER antibodies, they have not
elicited bnAbs in any species [17,23–27]. One possibility why gp41
MPER-containing immunogens fail to elicit bnAbs is that they are
not in native conformations. In particular, there is evidence that
the physiological form of the gp41 MPER to which 2F5 binds, the
‘‘prehairpin intermediate’’, is a unique structure that is only
transiently expressed upon engagement of the CD4 receptor and
chemokine co-receptors [11,28–30], implying that the repertoire
of gp41 MPER bnAb-producing B cells is present, but the gp41
MPER pre-hairpin intermediate form is not available for a
sufficient period of time to engage B cells.
The bnAb 2F5 and 4E10 have long hydrophobic CDR3 regions
[16,18] and exhibit polyreactivity to lipids and other autoantigens
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nicity is that gp41 MPER-specific bnAbs cannot be elicited
because the B cells from which they originate are subjected to
peripheral or central B cell tolerance mechanisms [34]. Such
mechanisms could include deletion, anergy, or receptor editing
and could be due to gp41 MPER cross-reactivity with as yet
unidentified self or environmental/commensural antigens and/or
to the viral lipid membrane [35,36].
While non-neutralizing gp41 MPER Ab responses have been
studied, virtually nothing is known about the B cell populations
that interact with and/or respond to the broadly neutralizing
epitopes of HIV-1 Env. One key question is whether MPER
epitope-specific B cells are lost to tolerance at some point during
B-cell ontogeny [35,37]. Another fundamental question is whether
B-cell interactions with gp41 MPER occur solely via paratopic
recognition by B cell receptors (BCR). For example, B cells can
interact with other parts of the HIV-1 Env through BCR-
independent mechanisms, such as binding gp120 outside conven-
tional antigen-binding regions in Ig [37] or via mannose C type
lectin receptors [38].
The goal of this study was to define B cell interactions with the
gp41 MPER epitope of one of the most potently and broadly
neutralizing antibodies known, the rarely-made mAb 2F5, and to
compare it with B cell interactions occurring with other HIV-1
epitopes. We chose to study murine B cells, since failure to induce
bnAbs to the gp41 MPER is not species-specific, and 2F5 cross-
reacts with human and murine self-antigens ([32] and G. Kelsoe,
unpublished results). Moreover, studies of B cell genetics and
ontogeny can be simplified in the mouse, where congenic strains
and developmental B-cell subsets are well-defined. In this study,
we have used tetramerized HIV-1 peptide epitopes [39] to identify
a novel type of interaction between BALB/c BCRs and the gp41
MPER. Characterization of this interaction reveals that it is non-
paratopic and instead mediated by Cm determinants expressed on
IgM
a but not IgM
b polypeptides. In addition, whereas this
frequent, non-paratopic binding of gp41 MPER represents a low
avidity interaction, it is sufficient to partially activate splenic B cells
in vitro. Finally, we demonstrate preferential gp41 MPER-specific
IgM
+ Ab production in polyclonally-activated BALB/c gp41
MPER-binding splenic B cells and in naı ¨ve BALB/c serum,
suggesting that natural non-neutralizing anti-gp41 MPER-specific
Abs are spontaneously produced by MZ and B1 IgM
a B cells.
Results
Generation and validation of gp41 MPER B cell tetramers
The 2F5 mAb, like all other HIV-1 bnAbs, is not normally
made during the course of natural HIV-1 infection, nor can it be
elicited in any species immunized by current HIV-1 immunogens.
However, non-neutralizing Abs specific for the gp41 MPER 2F5
epitope can readily be elicited by immunization in various species,
including mice ([23,40] and Haynes and Verkoczy, unpublished
results). To begin understanding what may be inherently different
about 2F5 (or 2F5-like) broadly neutralizing and non-neutralizing
Ab responses, we sought to characterize what B cell populations, if
any, specifically bound the gp41 MPER 2F5 epitope, and if such
interactions differed from those with 2F5 itself. To do this, we
generated APC-labeled tetramer reagents containing the gp41
MPER 2F5 epitope to allow for convenient and sensitive detection
of B cells by flow cytometry, by analogy to studies using tetramers
for identifying antigen-specific T cells [41]. We reasoned that
tetramerization of the gp41 MPER 2F5 epitope would i) more
physiologically mimic the multimeric nature of BCR interactions
with antigens, and ii) allow us to identify B cells with a larger range
of affinities for the 2F5 gp41 MPER epitope because of the
increased avidity conferred by its multimerization.
For these studies, tetramers specific for the 2F5 epitope of gp41
MPER (herein referred to simply as gp41 MPER) were made from
the peptide QQEKNEQELLELDKWASLWN; (corresponding to
residues 659–678 of the HIV-1 envelope). This peptide was chosen
because in addition to containing the original ELDKWA core
neutralization motif of 2F5, it contains additional residues flanking
this region which have been shown by several mapping/affinity
measurement studies to confer optimal binding of 2F5 to gp41
MPER [14,40,42,43] and thus represents the ideal, nominal 2F5
epitope. The specificity and quality controls to validate gp41
MPER-specific B-cell tetramers, as well as tetramer reagents to
other well-characterized HIV-1 Env epitopes, are summarized in
Fig. S1.
The gp41 MPER epitope interacts with large fractions of
naı ¨ve splenic B cells in a strain-specific manner
We first identified if and how splenic B-cell populations in naı ¨ve
BALB/c and C57BL/6 mice bound the APC-labeled gp41 MPER
tetramer by flow cytometry. We used mouse B cells to study since
the inability to elicit 2F5 or ‘‘2F5-like’’ bnAbs, as stated above, is
not a species-specific issue, yet B cell genetics and development are
best defined in mice, and thus we reasoned are best-suited starting
models to study this fundamental question. Strikingly, a large
fraction (,7%) of naı ¨ve splenic BALB/c B cells bound the gp41
MPER tetramer (Fig. 1A, upper right panel). In contrast,
frequencies of MPER binding by naı ¨ve splenic C57BL/6 B cells
was only 0.1–0.3% (Fig. 1A, upper left panel). Binding frequencies
of a control tetramer bearing an epitope from a conserved portion
of the gp120 V3 loop were low in both strains and comparable to
observed for MPER-binding by C57BL/6 splenic B cells. (Fig. 1A,
bottom panels).
We explored the nature of this strain-specific binding of gp41
MPER by labeling BALB/c and C57BL/6 splenic B cells with
gp41 MPER tetramer or tetramers bearing scrambled MPER
peptides over a wide concentration range. Elevated gp41 MPER
binding to BALB/c cells, relative to C57BL/6 B cells, was
observed at all concentrations of tetramers carrying MPER
peptide, as measured both by mean fluorescence intensity (MFI,
Fig. 1B, left panel) and the fraction of labeled B cells (Fig. 1B, right
panel). This MPER-specific binding was substantially elevated
relative to the scrambled peptide controls, ruling out binding
determined solely by charge or other general properties.
Importantly, saturating levels of gp41 MPER binding was attained
at 10 mg/10
6 splenocytes, when ,25% of all B cells were labeled,
the highest gp41 MPER/scrambled gp41 MPER binding ratio
was achieved at the sub-saturating concentration of 100 ng/10
6
splenocytes. For this reason, we employed this concentration of
tetramer reagent for all subsequent studies.
gp41 MPER-reactive BALB/c B cells are concentrated in
marginal zone and B1 B cell subsets
To examine how gp41 MPER-reactive B cells were distributed
among distinct B-cell compartments, we determined the frequen-
cies of gp41 MPER-reactive B cells within splenic and peritoneal B
cell subsets using two methods: by measuring the MFIs of distinct
B cell subsets (Table S1) or by enumeration of B cells labeled by
the gp41 MPER tetramer (Fig. 2 and Table S2). By both
measurements, gp41 MPER reactivity was strongest in marginal
zone (MZ) and peritoneal B1 B cell subsets of BALB/c mice (Fig. 2,
Tables S1, S2), two B cell fractions expressing high levels of IgM
(Fig. 2A and [44]) and restricted VH family repertoires (45,46). In
IgM
a-Restricted HIV-1 Binding
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7215Figure 1. Strain-specific gp41 MPER interactions with B cells. A) Representative histograms showing surface staining of 10
6 splenocytes from
unimmunized C57BL/6 and BALB/c mice with 100 ng of APC-labeled gp41 MPER or clade B V3 epitope-specific tetramers. Shown are singlet, live,
total B cell (CD19
+)-gated splenocytes. Numbers indicate percentages of tetramer-reactive B cells above background staining without tetramer. B)
Tetramer binding analysis of splenic B cell populations from unimmunized C57BL/6 and BALB/c mice using serial dilutions of APC-labeled gp41 MPER
or scrambled gp41 MPER epitope-specific tetramers to stain 10
6 splenocytes. APC MFIs or percentages of tetramer-reactive cells within singlet, live,
CD19
+ gates were measured and graphically represented. Data shown are representative of several experiments. C) Comparison of binding avidity of
C57BL/6 and BALB/c total splenic B cells to the gp41 MPER, as measured by APC MFIs of tetramer-reactive B cells. gp41 MPER tetramers (100 ng/10
6
cells) were used to surface-stain splenocytes and tetramer-reactive B cell MFIs (above staining with no tetramer) within the singlet, live, CD19
+ gate
was calculated and graphically represented. Data shown are taken from a representative experiment (mean6s.d of five mice).
doi:10.1371/journal.pone.0007215.g001
IgM
a-Restricted HIV-1 Binding
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7215Figure 2. Relative frequencies of gp41 MPER-reactive cells in B cell subsets. A) Representative surface staining with gp41 MPER tetramers
(100 ng/10
6 cells) in splenic and peritoneal B cell subsets from naı ¨ve BALB/c mice. For each subset, shown are open histograms indicating either the
APC-labeled scrambled gp41 MPER tetramer (left panels), or the gp41 MPER tetramer (right panels), relative to background staining without tetramer
(filled histograms). B cell populations in all tissues were gated as singlet, live, lineage
2, CD19
+B220
+ cells, and subsets within B cell fractions were
identified using published subfractionation schemes [44,74–76]. Numbers indicate the percentage of tetramer-reactive B cells from a representative
experiment (mean6s.d of five mice). B) Graphical representation of relative gp41 MPER reactivities in spleen (black) and peritoneal cavity (gray) B cell
subsets, as calculated from several flow cytometry experiments ($3 mice/experiment) as described in A). Numbers indicate the total mice analyzed.
doi:10.1371/journal.pone.0007215.g002
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expressing lower levels of membrane IgM (Fig. 2A and [44]) and
more diverse VH repertoires [45,46], exhibited lower levels of gp41
MPER binding. Examination of gp41 MPER reactivity in B-cell
subsets of C57BL/6 mice did not reveal increased levels of MPER
binding by MZ and B1a B cells (Table S2).
In addition to differing in overall frequencies and enrichment
to particular subsets, gp41 MPER binding also differed qualita-
tively in BALB/c and C57BL/6 strains with respect to MFI
binding patterns. In particular, the majority of MPER-reactive B
cells within BALB/c subsets shifted as ‘‘low avidity’’ shoulders,
with an additional, small fraction binding as a ‘‘higher-avidity’’
MFI tail (see Fig. 1A top right panel, 2A and MFI values in Table
S1). In contrast, gp41 MPER-reactive C57BL/6 B cells scattered
further out across the APC channel (Fig. 1A, top left panel, and
Fig. 1C).
Secreted IgM from in vitro activated BALB/c splenic B
cells are enriched for gp41 MPER reactivity
To determine whether the high frequency, strain-dependent
binding of gp41 MPER in IgM
hi B cell subsets was mediated by
membrane IgM or some other strain-specific molecule, we
activated splenocytes from naı ¨ve BALB/c and C57BL/6 mice in
vitro with BAFF+LPS and measured the fraction of total
(IgM+IgG) ELISpots that bound gp41-MPER peptide (Fig. 3).
Consistent with the high frequencies of gp41 MPER
+ BALB/c
splenic B cells observed by flow cytometry (Fig. 1A,B), ,17% of all
BALB/c Ab-secreting cells (ASC) secreted IgM that bound gp41
MPER at a frequency 3 fold higher amount than C57BL/6 gp41
MPER-specific ASCs. Consistent with high frequencies of MPER-
binding by IgM
hi B-cell subsets (Fig. 2 and Tables S1 and S2),
,20% of IgM ELISpots were labeled by gp41 MPER peptide,
whereas ,5% of IgG ELISpots were gp41 MPER-specific (Fig. 3
C,D). Furthermore, at 500 input cells/well, ,75% of total Ig,
gp41 MPER-specific ASCs were IgM
+.
Additional evidence for elevated, strain-dependent gp41 MPER
reactivity came from spontaneous elevations in gp41 MPER-
specific serum Ab from BALB/c mice, compared to C57BL/6
mice (Fig. 3E). This increase of gp41 MPER binding by BALB/c
serum Ab was confirmed by Surface Plasmon Resonance (SPR)
binding analysis (Fig. S2). Consistent with ELISpot data, serum Ab
with the highest gp41 MPER reactivity were predominantly of the
IgM isotype (Fig. 3E).
HIV-1 gp41 MPER binding by naı ¨ve BALB/c B cells is
epitope-specific
To exclude spurious, non-specific binding by gp41 MPER, we
examined if binding was eliminated upon pre-incubating spleno-
cytes with excess unlabeled gp41 MPER or scrambled gp41
MPER tetramers (homologous and heterologous competition,
respectively) prior to labeling with APC-conjugated MPER
tetramers (Fig. 4A). Pre-incubation with unlabeled gp41 MPER
tetramer (but not scrambled tetramer) inhibited binding of the
APC-labeled gp41 MPER tetramers .90%, confirming that gp41
MPER binding to BALB/c B cells was indeed epitope-specific.
We next pre-incubated BALB/c B splenocytes with increasing
molar ratios of unlabeled gp41 MPER tetramers and two
heterologous competitors: either i) unlabeled scrambled gp41
MPER or ii) a double-stranded DNA (dsDNA) mimic tetramer
made from the R4A peptide DWEYSLWLSN [47,48]. Dose-
dependent inhibition of APC-labeled gp41 MPER peptide binding
was observed with homologous competition, as measured by the
percentage of gp41 MPER
+ B cells (Fig. 4B) or by MFI (data not
shown). Importantly, incubation of dsDNA tetramers showed
minimal competition with gp41 MPER binding, indicating that
any potential dsDNA-specific BALB/c B cells were unrelated to
those specific for gp41 MPER.
We then asked if this unusual, high-frequency ($5%) binding to
BALB/c B cells was unique to gp41 MPER. To do this, we made
tetramers from peptides spanning conserved epitopes of two other
well-characterized HIV-1 Env regions, the V3 and immunodo-
minant (ID) loops of gp120 and gp41, respectively, and tested the
ability of these reagents to stain naı ¨ve BALB/c splenocytes. The
specificity/quality controls of the gp120 V3 and gp41 ID-specific
tetramer reagents are shown in Fig. S1. We chose these two HIV-1
Env regions to compare with gp41 MPER because they are
conserved, conformationally accessible, and known to be immu-
nogenic i.e. capable of eliciting robust epitope-specific Ab
responses [49,50]. We reasoned that if gp41 MPER tetramer
binding to B cells represents an inherently unique feature of the
gp41 MPER epitope (rather than specificity and/or avidity issues
exhibited by all HIV-1 epitope-specific tetramer reagents), then
gp41 ID and V3-specific tetramers should bind B cells at
frequencies seen by conventional antigens. In response to
immunization, such clonal, antigen-specific binding occurs at
relatively low-frequencies i.e. 0.01–1% (47), and in unimmunized
mice, likely occurs at frequencies several orders of magnitude
lower yet. Indeed, when we incubated naı ¨ve BALB/c splenocytes
with either of the two V3 tetramers, (62.19 V3 and clade B V3), or
with the gp41 ID-specific reagent, no tetramer reagent other than
gp41 MPER labeled B cells at frequencies significantly higher than
their respective scrambled tetramer controls (all scrambled
controls bound with background levels of ,0.1–2% of total B
cells; Fig. 4C). We thus conclude that the high-frequency binding
of BALB/c B cells to gp41 MPER is specific for, and unique to this
epitope.
The gp41 MPER epitope interacts with large fractions of
BALB/c B cells by specifically binding to B cell receptors
(BCRs)
The frequencies of BALB/c B cells and secreted, IgM ELISpots
that bound gp41 MPER peptide was much higher than expected
for any antigen-specific population. Although the ELISpot data
indicated that MPER peptide binding was mediated by surface
IgM, we examined whether gp41 MPER could interact with
BALB/c B cells via other surface receptors such as Mannose C
type Lectin Receptors (MCLRs; through which gp120 has been
reported to interact with [38]). We first examined relative effects of
BCR and MCLR ligands to block and/or internalize gp41 MPER
(Fig. 4D). APC gp41 MPER signal was significantly abrogated
following incubation with an anti-Ig, but not with MCLR ligands
mannose and alpha-methyl-mannopyranoside, suggesting speci-
ficity of gp41 MPER for BCR.
We next determined if anti-Ig mediated downmodulation of
gp41 MPER binding was due to internalization of gp41 MPER/Ig
complexes by pre-incubating with anti-Ig Abs (Fig. 4E). MPER
peptide downmodulation with anti-Ig at 37uC was rapid (.80%
by 15 min), and was not observed at 4uC, suggesting that BCR
internalization accounted for diminished gp41 MPER binding. To
further determine whether bound gp41 MPER associated with
membrane Ig, we performed co-capping experiments (Fig. 4F).
Indeed, gp41 MPER tetramer co-capped with surface Ig in
BALB/c splenic B cells stimulated with both reagents. Collectively,
our results demonstrate that gp41 MPER interacts with large
fractions of naı ¨ve BALB/c B cells by binding to membrane-
associated Ig.
IgM
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7215Figure 3. Analysis of gp41 MPER-specific ASCs from in vitro-activated splenocytes and gp41 MPER-specific serum Abs from naı ¨ve
BALB/c and C57BL/6 mice. A) ASCs were measured by ELISPOT analysis of BALB/c or C57BL/6 splenocytes cultured for 72 h in LPS+BAFF, and the
gp41 MPER-specific BALB/c hybridoma cell line, 13H11, for comparison. One of many replicate wells is shown for each panel. B) Graphical comparison
of gp41 MPER-specific ASC frequencies in BALB/c and C57BL/6 cultured splenocytes. Shown are representative gp41 MPER-specific or dsDNA mimic-
specific ASC values over a range of two-fold dilutions of 13H11 or input BALB/c or C57BL/6 splenocytes, all cultured in triplicate wells as described in
A). The lowest cell dilution of total ASCs for each strain is also shown and was used to calculate the fraction of gp41 MPER-specific ASCs. C)
Representative ELISPOTs of IgG or IgM-specificity within total and gp41 MPER-specific ASC from BALB/c splenocytes cultured as described in A). As a
positive control for IgG-reactivity, also shown are IgG
+ fractions within total and gp41 MPER-specific ASCs from13H11. D) Graphical representation of
IgG, IgM, and IgM+IgG-specific fractions within total or gp41 MPER-specific ASCs, plotted as described in A). E) ELISA of C57BL/6 and BALB/c naı ¨ve
serum reactivity to gp41 MPER. Naı ¨ve serum from five, 12 wk, female BALB/c and C57BL/6 mice were measured against plate-bound gp41 MPER, as
described in Materials and Methods. Naı ¨ve serum from five, age and sex-matched RAG1
2/2 and MRL/lpr animals (the latter exhibit significant gp41
MPER reactivity; Verkoczy and Haynes, unpublished results) were included as negative and positive controls, respectively.
doi:10.1371/journal.pone.0007215.g003
IgM
a-Restricted HIV-1 Binding
PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7215Figure 4. Specificity of gp41 MPER interactions with total B cells. A) Representative histograms showing cold inhibition of gp41 MPER
binding to BALB/c B cells (100 ng/10
6 splenocytes). Homologous competitor (unlabeled gp41 MPER tetramer) or heterologous competitor (scrambled
gp41 MPER tetramer) were pre-incubated at 10-fold molar excess. Numbers represent the percentage of gp41 MPER-reactive B cells within singlet,
live, CD19
+ populations. B) Graphical representation of inhibition with increasing amounts of unlabeled gp41 MPER or heterologous (scrambled gp41
or dsDNA mimic) tetramer competitors. Data were calculated as in A) and represent the average of three experiments. C) Interactions of total BALB/c
splenic B cells with various HIV-1 epitope-bearing B cell tetramers. Splenocytes were stained (100 ng tetramers/10
6 cells) with gp120 V3, gp41
immunodominant, and gp41 MPER-specific B cell tetramers or their scrambled counterparts. Plotted are average percentages of tetramer-reactive B
cells within singlet, live, CD19
+ populations from three independent experiments. D) B cell tetramer reactivity in BALB/c splenocytes treated with BCR
and MCLR ligands. 10
6 splenocytes from naı ¨ve BALB/c mice were stained with 100 ng gp41 MPER tetramers, either alone, or pre-treated for 45 min at
37uC with anti-Ig, mannan, or a-methyl-mannopyranoside. Plotted are the percentages of tetramer-reactive B cells within singlet, live, CD19
+
populations from an average of three experiments. E) Effect of BCR internalization on gp41 MPER surface staining of BALB/c splenic B cells. Anti-Ig
stimulation of purified BALB/c splenic B cells for various times (in min.) and calculation of remaining surface-bound APC-labeled gp41 MPER was done
as described in materials and methods; shown are results of a representative experiment. F) Cap formation of anti-Ig/gp41 MPER B cell tetramer
complexes in BALB/c splenic B cells after BCR cross-linking, as described in materials and methods. An example of a capped B cell after 15 min of anti-
Ig stimulation is shown, either as individual immunofluorescent stains of Alexa488 Wheat Germ Agglutinin, APC gp41 MPER tetramers, R-PE-anti
IgM+IgG, or merged.
doi:10.1371/journal.pone.0007215.g004
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7215High frequency gp41 MPER binding to naı ¨ve B cells maps
to the Igh
a locus
Our results demonstrating strain-specific interactions of gp41
MPER with large fractions of naı ¨ve B cells through membrane
IgM raised the possibility that gp41 MPER does not bind to VH
regions in conventional antigen-specific fashion, but instead, binds
allotypic residues in conserved VH framework and/or CH
domains.
To determine whether the frequent gp41 MPER binding by
BALB/c B cells is controlled by the Igh
a locus, we determined the
frequencies of B cells binding gp41 MPER tetramer in congenic
mouse strains differing solely at their Igh loci (Fig. 5). Control
tetramers carried the epitopes of clade B V3. Strikingly, we found
that high frequency gp41 MPER binding segregated with the Igh
a
allele, as C57BL/6 mice homozygous for the BALB/c Igh
a locus
exhibited gp41 MPER binding identical to BALB/c animals
(Fig. 5). Conversely, congenic BALB/c mice homozygous for the
C57BL/6 Igh
b locus lost gp41 MPER binding (Fig. 5).
High frequency, Igh
a-restricted gp41 MPER binding maps
to non-paratopic regions of IgM
Preferential interaction of gp41 MPER with IgM-expressing B-
cell subsets (Fig. 2, Tables S1, S2) and secreted IgM (Fig. 3B),
along with genetic demonstration of Igh
a-restricted binding (Fig. 5)
strongly imply that gp41 MPER binds to naı ¨ve B cells via IgM
a-
restricted determinants. Since interactions can occur between
BCRs and B-cell superantigens (sAg) through VH framework
(FRW) or Fc (reviewed in [37]), we examined where gp41 MPER
peptide bound to IgM
a molecules.
First, we performed surface plasmon resonance analyses of gp41
MPER binding to whole, monomeric or F(ab)2 IgM fragments of
two purified IgM mAbs, differing in allotype (IgM
a and IgM
b), but
with the same antigenic specificity to TNP-KLH. We first
examined binding of monomeric IgM
a and IgM
b to gp41 MPER
(Fig. S3). As expected, preferential binding with IgM
a was
observed: this binding was specific for the gp41 MPER 2F5
epitope, as the scrambled gp41 MPER peptide or a peptide
corresponding to a region within gp41 MPER, but outside the 2F5
epitope (gp41 MPER HR1) exhibited little or no binding. This
binding reflected low avidity interaction(s), ,1 log lower avidity
than did 2F5-gp41 MPER interactions (Kd values were 275.5 and
10 nM, respectively), as calculated by surface plasmon resonance
analysis (Table S3). Importantly, comparison of gp41 MPER
binding by F(ab)2 IgM
a fragments or by whole, monomeric IgM
a
revealed that F(ab)2 IgM
a did not bind the gp41 MPER epitope
(Fig. 6A). This loss of binding to the gp41 MPER by F(ab)2 IgM
a
fragments was unlikely due to loss of functionality/conformational
integrity since their TNP specificity was retained (Fig. S4). We
conclude that allotypic determinants in the IgM
a constant region
are critical for the binding of gp41 MPER to BALB/c B cells.
These studies, as well as the fact that MZ and B1 cells, in
addition to expressing higher IgM levels, also contain more
restricted VH repertoires [45,46,51], cannot exclude the possibility
of Igh
a-linked variable region determinants, for example within
the FRW of selected VH families that may also contribute to gp41
MPER binding. To test this possibility, we determined the pattern
of VH family usage in the expressed IgM
+ VH repertoire of gp41
MPER tetramer-sorted splenic BALB/c B cells (Fig. 6B). Com-
pared to total IgM
+ BALB/c B cell populations, we found that
Figure 5. Analysis of IgH allotype involved in gp41 MPER epitope interactions with the BCR. Representative histograms showing staining
of 10
6 splenocytes from unimmunized C57BL/6 and BALB/c inbred strains (congenic for IgH
a and IgH
b allotypic determinants) with 100 ng of gp41
MPER or clade B V3-specific APC-labeled tetramers. Numbers indicate the percentage of tetramer-reactive cells within singlet, live, CD19
+-gates.
Results are representative of several experiments; similar results were seen in B cells from BM, LN, and PBL (not shown).
doi:10.1371/journal.pone.0007215.g005
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PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7215Figure 6. Mapping of IgM regions required for allotype-restricted binding to gp41 MPER. A) Surface plasmon resonance analysis of IgM
a
and IgM
b binding to gp41 MPER. Monomeric or F(ab)2 fragments derived from IgM
a and IgM
b mAbs were injected over biotinylated (B) gp41 MPER
nominal epitope peptide, anchored to a SA-coated sensor chip, as shown in the top left-hand schema, and described in materials and methods. mAbs
17b and 2F5 were run as negative and positive controls for gp41 MPER binding, respectively. Results are representative of two independent
experiments. B) VH family usage in gp41 MPER-sorted IgM
+ B cells from naı ¨ve BALB/c mice. Independent 59 RACE clones (n) were derived from
purified BALB/c splenic B cell populations, either unsorted or sorted into gp41 MPER
+ fractions and subjected to IgM-specific 59 RACE analysis, as
described in Materials and Methods. VH family frequencies within expressed VH repertoires was determined by Ig Blast analysis of sequences.
Statistical comparisons between unsorted and gp41 MPER+ fractions were performed using the Fisher Exact test (*, p,0.05; **, p,0.01). Results are
pooled from multiple PCR amplifications of two sorts. VH families are represented in the 59 to 39 order by which they map to the VH locus.
doi:10.1371/journal.pone.0007215.g006
IgM
a-Restricted HIV-1 Binding
PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e7215most VH families were utilized at statistically comparable levels in
gp41 MPER-reactive B cells, with the exception of two
overutilized VH families: 36–60 and 7183. From this analysis,
we conclude that allotype-restricted gp41 MPER interactions with
IgM
a require Fc CH domains, but that determinants of the VH36-
60 and 27183 families may also play a role.
Igh
a restricted binding of gp41 MPER at residues distinct
from those required for bnAb 2F5 binding/neutralization.
To determine which aa residues in the gp41 MPER epitope
mediate high frequency, low affinity binding to IgM
a B cells, we
created a series of MPER peptide variants by alanine substitution
(Fig. 7A) and compared their binding of gp41 MPER with 2F5
(Fig. 7B, top panel) to binding with BALB/c splenic B cells (Fig. 7B,
middle panel). Consistent with previous studies [18,20], we found
that binding of 2F5, required residues 671D and 673 W within the
core 2F5 neutralization epitope ELDKWA (Fig. 7B, top panel).
Interestingly, gp41 MPER binding to BALB/c B cells mapped to
660Q and a 677 W, both located outside the core 2F5 epitope
(Fig. 7B, middle panel).
To extend this result, we generated splenic fusions from naı ¨ve
IgH
a and IgH
b congenic BALB/c mice and screened them for
gp41 MPER reactivity by flow cytometry using gp41 MPER
tetramers. Consistent with the IgM
a requirement for gp41 MPER
binding, we did not identify gp41 MPER-reactive IgM
b, or IgG
a
or IgG
b clones; we did, however, identify four gp41 MPER-
reactive IgM
a hybridoma lines (data not shown). Of these, we used
the cloned hybridoma, 9G8, with the highest gp41 MPER
reactivity (as determined by MFI), to map gp41 MPER-IgM
a
interactions (Fig. 7B, lower panel). Strikingly, we found that the
660Q and 677W residues required for binding BALB/c splenic B
cells were also critical for binding to 9G8 cells. Since the 671D and
673W residues of gp41 MPER interact with HC CDR regions
from the 2F5 antigen-binding pocket, our finding that different
gp41 MPER residues are required for IgM
a-specific interactions is
consistent with such interactions occurring in IgM Fc or possibly,
VH FRWs.
gp41 MPER tetramerized peptides can induce partial B
cell activation in vitro
To determine if gp41 MPER interactions with IgM
a could elicit
the activating signals required for biological responses, we assessed
BCR-proximal signaling events in BALB/c splenic B cells ligated
with gp41 MPER tetramers. First, we determined the induction of
protein tyrosine phosphorylation in cells incubated with saturating
concentrations (20 mg/10
6 cells; see Fig. 1b) of gp41 MPER
tetramer (Fig. 8A). Under the assumption that ,20–25% of the
total B cells bind saturating amounts of gp41 MPER tetramers,
tyrosine phosphorylation was assessed in lysates containing a 4:1
mixture of resting:anti-IgM stimulated BALB/c splenic B cells.
gp41 MPER tetramers induced rapid and reproducible patterns of
protein phosphorylation (Fig. 8A, lanes 5–7), albeit in quantities 2-
to 3-fold lower than that generated from anti-IgM ligation of equal
numbers of B cells (Fig. 8A, lanes 8–10). In addition, only selected
proteins were phosphorylated, including Syk, PI3K p110d, PLC-
c2, and one or more of the Src kinase family members Lyn, Fyn,
or Blk, (putatively represented by 72, 110, 130, and 56–60 kDa
bands, respectively). Importantly, incubation of B cells with
scrambled gp41 MPER tetramer did not induce protein
phosphorylation above background levels (Fig. 8A, lanes 2–4).
To distinguish whether all B cells that bound gp41 MPER
tetramers signaled weakly, or alternatively, if a small B-cell subset
was preferentially activated, we measured Erk protein phosphor-
ylation in BALB/c splenic B cells exposed to gp41 MPER or anti-
IgM by intracellular FACS analysis (Fig. 8B). Because this
approach allowed us to gate anti-Ig or gp41 MPER peptide-
ligated B cells, the amount of anti-Ig and gp41 MPER-induced
Erk phosphorylation could be compared on a cell-per-cell basis.
Consistent with phosphoblotting analyses, detectable, but damp-
ened induction of phosphorylated Erk was seen with gp41 MPER
stimulation (Fig. 8B, top panels) relative to anti-Ig ligation (Fig. 8B,
lower panels). Howver, Erk phosphorylation kinetics differed
between gp41 MPER and anti-Ig stimulation. Specifically, peak
gp41 MPER-induced Erk phosphorylation persisted at 30 min,
whereas anti-Ig induced Erk phosphorylation peaked by 10 min.
Importantly, the entire population of gp41 MPER-gated B cells
showed modest Erk activation, suggesting that all gp41 MPER-
ligated cells were equivalently activated.
Overall, these results demonstrate that gp41 MPER can
generate BCR, but relative to anti-Ig stimulation, these elicit
weak and/or partial BCR-proximal signaling patterns. We
conclude that gp41 MPER interactions with IgM
a may produce
signals distinct from those elicited by higher-affinity, paratopic
BCR cross-linking.
Discussion
In this study, we show that the 2F5 epitope of the HIV-1 gp41
MPER interacts with BALB/c MZ and B1 IgM
a B cells in a
manner that is distinct from traditional, clonal (paratopic) binding
by IgM
b B cells. This unusual binding is also distinct from the
interaction of other HIV-1 Env epitopes with IgM
a or IgM
b B
cells. These non-paratopic interactions are frequent (Fig. 1B) and
exhibit remarkable specificity, as demonstrated by ELISpot
analysis (Fig. 3), cross-epitope competition assays (Fig. 4A,B) and
biochemical/immunohistochemical evidence of specificity for sIg
(Fig. 4D–F). Secondly, our data demonstrate that these interac-
tions occur between IgM
a allotypic determinants not present on
F(ab)2 fragments (Figs. 5,6) and involve gp41 MPER residues
660Q and 677W (Fig. 7), distinct from those known to be critical
for bnAb 2F5 neutralization. Thirdly, gp41 MPER-IgM
a interac-
tions are low avidity, as determined by: i) i) SPR binding
measurements of gp41 MPER with IgM
a (Table S3) and ii)
elicitation of weak/incomplete proximal B cell activation events by
gp41 MPER (Fig. 8).
One obvious question arising from this study is whether gp41
MPER exhibits B cell sAg activity. Classical B-cell sAgs, like the S.
aureus protein A subunit (SpA), can bind to and activate large
populations of B cells, may cause selective deletion of MZ and B1
B cell subsets, and bind to B cells based on VH family usage
[37,52]. Similarly, sAg interactions of HIV-1 gp120 with human B
cells have been described (reviewed in [37] and [53–56]), resulting
in a VH3-skewed repertoire in HIV-1 infected individuals
(reviewed in [57] and [58–60]). Characteristics of gp41 MPER
binding to IgM
a described in this study that are comparable to
SpA-BCR or HIV gp120 sAg include: 1) the large fraction of total
B cell populations bound by gp41 MPER via BCR HCs, 2)
preferential binding to MZ and B1 B cell populations 3) non-
paratopic binding of gp41 MPER 4) partial deletion of MZ and B1
B cells in gp41 MPER-immunized BALB/c mice (L. Verkoczy and
B. Haynes, unpublished results).
Our data suggest that non-clonal binding of gp41 MPER to B
cells requires IgM CH (Fig. 6A), providing a straightforward
explanation for why a large portion of MZ B cells have uniformly
higher gp41 MPER reactivity (Fig. 2A and Table S1) than MF B
cells (which have comparable sIg densities, but lower IgM
expression). While the specificity of gp41 MPER for CH is not
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a.A )List of peptides (annotated numerically
according to position of substitution) used to make mutant tetramers with sequential alanine substitutions (in red) along the gp41 MPER region
containing the nominal 2F5 epitope. B) Comparison of gp41 MPER residues required for binding bnAb 2F5 with those required for allotypic
interactions with IgM. Shown is relative binding of mutant tetramers with either 2F5 (upper panel), naı ¨ve BALB/c total splenic B cells (middle panel),
and 9G8 (lower panel). Tetramers with corresponding substituted positions in the 2F5 epitope are indicated on the x-axis, with those in blue and red
representing mutated residues with .3 and .10 fold binding reductions, respectively. For measuring mutant tetramer binding to 2F5, unlabeled
versions of tetramers were used in SPR analysis, as described in Materials and Methods. For measuring binding of mutant tetramers to 9G8 and to
naı ¨ve BALB/c B cells, APC-labeled tetramers were used for staining splenocytes (100 ng/10
6 cells), followed by calculating APC MFIs of singlet, live,
total B cells after subtracting background MFIs in unstained cells. Data shown are an average of two experiments.
doi:10.1371/journal.pone.0007215.g007
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PLoS ONE | www.plosone.org 11 October 2009 | Volume 4 | Issue 10 | e7215Figure 8. Analysis of proximal B cell signaling/activation events in response to ligation with gp41 MPER. A) Purified splenic B cells from
naı ¨ve BALB/c mice, either incubated with medium alone (time=0) or stimulated with 20 mg/ml scrambled gp41 MPER tetramer, gp41 MPER tetramer,
or F(ab)’2 anti-IgM for indicated times were assessed for total phosphotyrosine proteins by immunoblotting (top panel). Lower panel shows the same
blot, re-probed with a GAPDH-specific Ab. Selectively activated proteins in response to gp41 MPER ligation are indicated by arrows and values below
lane numbers indicate relative phosphorylation levels normalized to anti-phosphotyrosine/GAPDH signal ratios in resting (time=0) cells. B) Left:
Intracellular FACS staining analysis of phosphorylated Erk levels in naı ¨ve BALB/c splenocytes, either unstimulated (filled histograms) or stimulated for
3–30 min (open histograms) with 20 mg/ml APC-labeled gp41 MPER tetramer (top panel) or 10 mg/ml APC-labeled anti-IgM or (lower panel). Data are
gated on B220+IgM (for anti-IgM stimulated samples) or on B220+tetramer (for gp41 MPER-stimulated samples). The upper left hand panel shows Erk
signal levels in resting cells relative to staining with an isotype control (dotted line). Numbers indicate the percentage of cells with phosphorylated
Erk. Right: Relative Mean Fluorescence Intensity (MFI) of phospho-Erk1/2-PE signal +/2 SD from three experiments in which naı ¨ve BALB/c splenocytes
were either left unstimulated (2) or stimulated for 10 min. with 10 mg/ml anti-IgM or scrambled gp41 MPER/gp41 MPER tetramers. Mean levels of
phosph-Erk1/2-PE in unstimulated splenocytes were arbitrarily set at 100. Significance values were determined by a two-tailed Student’s test: *,
p#0.05; **, p#0.01; NS, not significant.
doi:10.1371/journal.pone.0007215.g008
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which was first characterized in the context of its interactions with
Fc regions [61,62]; subsequently SpA was shown to have VH
FRW-binding properties [62]. Another intriguing feature of gp41
MPER interactions with B cells is the segregation of binding with
IgM
a determinants (Figs. 5, 6). Interestingly, this characteristic is
shared with T15, a dominant, SpA-reactive, anti-phosphorylcho-
line (PC) idiotope on B1 B cells, whose allotypic determinants are
key in shaping the anti-PC B cell repertoire and humoral response
[63,64]. Immunization/neonatal challenge studies with gp41
MPER in BALB/c and C57BL/6 IgH congenic strains are
currently underway to determine if/how gp41 MPER might
exhibit sAg activity on B cell differentiation and development.
It is also interesting that gp41 MPER reactive B cells
preferentially use the proximal VH families 36–60 and 7183.
While this could simply be correlational i.e. due to innate IgM
hi B
cell subsets also overutilizing proximal VH families (for example,
skewing of VH7183 in B1a cells; [65]), an intriguing alternative is
that IgM
a allotypic determinants in 7183 and 36–60 VH FRW
regions (in combination with CH determinants), may form a gp41
MPER-specific idiotope, a situation analogous to the T15 sAg-
reactive idiotope [63]. Future genetic experiments using BAB/14
congenic mice [66], with a recombination between VH and CH
allotypes (i.e. having an Igh
a (BALB/c) VH region and an Igh
b (B6)
CH region) should definitively address any potential, additional
contribution of the VH region in the non-clonal binding of Igh
a
determinants to the gp41 MPER.
An alternative possibility for preferential gp41 MPER interac-
tions with IgM
a allotypic determinants is that determinants within
(or proximal to) the Igh
b locus may encode a self-antigen
mimicked by gp41 MPER. This situation would be analogous to
MMTV infection-susceptible congenic mouse strains, which retain
endogenous MMTV-like sAg genes that delete sAg-binding T cells
with the same Vb specificities as those encoded by the infectious
virus during the shaping of the TCR repertoire (reviewed in [67]).
Assuming gp41 MPER sAg IgM
a-specific binding were due to the
lack of IgM
b endogenous allotype-encoded determinants, the
differential binding patterns to gp41 MPER in BALB/c and
C57BL/6 B cell subsets may therefore reveal an inherent
susceptibility of the endogenous gp41 MPER-specific B cell
repertoire to: i) an IgM
b allotype-specific endogenous sAg (that
cross-reacts with gp41 MPER), reflected by the uniformly higher
sAg-mediated binding across all IgM
a subsets, and ii) the same or a
different IgM
b-specific endogenous sAg selectively targeting innate
subsets, reflected by further preferential elevations in IgM
a MZ
and B1 subsets. We are currently generating transgenic Igh
a and
Igh
b congenic mice overexpressing gp41 MPER to address these
possibilities.
The demonstration that gp41 MPER interactions with IgM
a
allotypic determinants outside antigen binding pockets are capable
of eliciting BCR-proximal activation signals makes the important
link between this unusual binding and its potential impact on gp41
MPER-specific humoral responses. In this context, one obvious
question arising from our studies is what are the physiological
consequences of weak and/or incomplete signaling by gp41
MPER (Fig. 8). One possibility is that incomplete activation of B
cells by low affinity MPER binding could suppress the T-
independent component of MPER Ab responses, as has been
reported for low-affinity, weak/partial agonists [68]. This potential
lack of IgH
a T-independent anti-gp41 MPER responsiveness
could be enhanced by efficient T-B collaborations in vivo due to
preferential recognition of certain TH cells for IgH
a, since there is
precedent for T cell-specific recognition of IgH
a C regions [69,70].
Two additional possibilities related to avidity and frequency of
MPER-IgM
a interactions, (but functionally independent of the
interacting allotypic determinants), could be invoked. First,
incomplete weak or incomplete BCR signaling by low affinity
MPER binding could deliver anergic signals in gp41 MPER-
interacting peripheral B cells, thus blocking an antigen-specific
response through BCR, analogous to antagonistic signals delivered
by low affinity BCR and TCR ligands. Secondly, B cell subsets
with different signaling thresholds could be differentially modu-
lated by MPER. In particular, because MZ B cells (relative to MF
B cells) require weaker BCR signals [71–73], and are more
sensitive to anti-IgM mediated apoptosis [51], the large fraction of
MPER-specific MZ B cells in BALB/c mice may be preferentially
susceptible to deletion via MPER ligation through BCR, a
possibility that would be consistent with reduced MZ B cell
populations in gp41 MPER-immunized BALB/c mice (Verkoczy
and Haynes, unpublished results).
Regardless of the signals that interactions between gp41 MPER
and IgM
a generate, we propose that distinct BCR interactions with
gp41 MPER exist in BALB/c and C57BL/6 mice that may reflect
two distinct immunoregulatory mechanisms controlling MPER-
specific bnAb responses: 1) high-affinity, low-frequency, develop-
mentally-regulated patterns of ‘‘antigen-specific’’ gp41 MPER
binding in C57BL/6 mice (M.Holl, L.Verkoczy, B.Haynes, and
G.Kelsoe, unpublished data) presumably involving paratopic
interactions with long, hydrophobic HC CDR3 regions of 2F5
or ‘‘2F5-like’’-expressing B cells, and 2) ‘‘sAg-like’’ binding in
BALB/c mice in this study, representing high frequency, low-
affinity non-clonal interactions of IgM
hi B cell subsets with gp41
MPER, capable of eliciting sub-optimal and/or altered B cell
signaling. However altered or dampened signals generated by the
gp41 MPER may interfere with an effective humoral response to
this region (i.e. either triggering a robust non-neutralizing MPER
Ab responses and/or eliciting poor bnAb anti-MPER responses),
the finding that unique gp41 MPER residues are involved in such
interactions may provide clues for immunogen design. Specifically,
designing gp41 MPER immunogens that abrogate allotype-
regulated MPER binding may yield immunogens with only
antigen-specific B cell activation capabilities.
Materials and Methods
B cell tetramer synthesis and validation
N-biotinylated, linker/spacer-containing peptides used to make
tetramers are detailed in Table S4 and Fig. 7A. Peptides were
synthesized and purified using reverse-phase HPLC (Primm
Biotechnology). To produce tetramerized forms of each peptides,
200 mM peptide and 6 mM APC-labeled streptavadin (SA) were
combined at equal volumes, and mixtures were incubated at 4uC
for 4 h. Unbound peptide was removed from peptide-APC
complexes by centrifugal filtration using an Amicon Centriprep
YM30 column (Millipore Corporation). Purified tetramer prepa-
rations were determined using the Micro BSA protein assay kit
(Pierce Biotechnology).
Mice and gp41 MPER-specific hybridomas
Female C57BL/6, BALB/c, B6Igh
a, and CB17 (BALBc Igh
b)
inbred mouse strains (8–12 wks of age) were purchased from
Charles River Laboratories. All mice were housed in the Duke
University Animal Facility in a pathogen-free environment with
12 h light/dark cycles at 20–25uC under AALAC guidelines and
in accordance with all Institutional Animal Care and Use
Committee and Duke University Institutional Biosafety Commit-
tee-approved animal protocols. The IgG1 anti-gp41 MPER cell
line 13H11 was grown and maintained in DMEM media (Gibco)
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24 M 2-ME and penicillin/streptomycin
(P/S) antibiotics as previously described [39]. The 9G8 IgM
a anti-
gp41 MPER hybridoma cell line was generated from a hybridoma
fusion performed using P3X63/Ag8 murine myeloma cells and
spleen cells taken from an unimmunized BALB/c mouse.
In vitro cultures and ELISpot
ELISpot plates (Millipore) were coated with 2 mg/ml (50 ml/
well) of goat anti-mouse Ig(H+L), goat anti-mouse IgM or goat
anti-mouse IgG in 0.1 M Carbonate Buffer (pH 9.5) overnight at
4uC. Washing/Blocking buffer contained 1x PBS (pH 7.4), 0.1%
Tween-20 and 0.5% BSA (USB). For detection of antigen-specific
ASC, LPS+BAFF-activated B cells were washed and plated at
0.524610
3 cells/well in triplicate. Cells were incubated at 37uC
in a humidified CO2 incubator for 4 h with IMDM media
containing 10% FCS, 10
24 M 2-ME and penicillin/streptomy-
cin. Plates were washed and re-blocked for 1-2 d using blocking
buffer, and membranes were probed with 20 mMb i o t i n -
DP178Q16L peptide (YTSLIHSLIEESQNQQEKNEQELLE-
LDKWASLWNWF; containing the gp41 MPER 2F5 epitope),
for 2 h at room temperature. SA-AP (Southern Biotech) and
SIGMA FAST BCIP/NBT (Sigma) were used to develop antigen-
specific spots. For detection of total ASC, LPS+BAFF-activated B
cells were plated, washed and re-blocked as described above, and
membranes were detected with goat-anti-mouse IgM-AP and
IgG-AP.
ELISA
For determination of gp41 MPER-specific serum Ab titers,
ELISA was performed by coating high-binding microtiter plates
with the peptide QQEKNEQELLELDKWASLWN; (correspond-
ing to residues 659–678 of the HIV-1 envelope and containing the
optimal, nominal gp41 MPER 2F5 epitope; 0.2 mg/well) as
previously described [40].
Flow cytometry
FACS staining of single cell suspensions ($2610
6) was
conducted using pre-mixed combinations of fluorochrome-labeled
Abs and APC-conjugated B cell tetramers at empirically-
determined optimal concentrations. All Abs were from BD unless
otherwise stated. Primary antibodies used were: PerCP anti-B220,
FITC anti-IgD, FITC, PE or PE-Cy7 anti-IgM, PE anti-CD5,
FITC anti-CD11b, PE-Cy7 anti-CD19, FITC anti-CD21, PE-Cy7
anti-CD23 (eBiosciences), and PE-Cy7 anti-CD93 (eBiosciences).
Other reagents included biotinylated Abs against dump channel
markers: Thy1 (Abcam), F4/80 (Abcam), CD11c, Gr-1, TER-119,
and NK-1.1, secondary staining SA-Texas Red conjugate; v-
amine live/dead violet dye (Molecular Probes), and Fc block (anti-
CD16/32).
Staining was conducted at 4uC in several sequential steps in
FACS staining buffer (1X PBS with 2% FCS, 0.1% NaN3),
washing twice between steps. Cells were first incubated with v-
amine live/dead dye for 15 min, then stained with APC-labeled
tetramers for 30 min (and in some experiments, cold tetramer was
incubated at 10 fold molar excess for 1 h, prior to staining with
APC-labeled tetramers). Cells were then stained with Fc block,
followed by incubation with combinations of primary Abs, and
secondary staining with SA-Texas Red, each for 30 min. Data
($2.5610
5 events/sample) were acquired using an LSRII flow
cytometer and Cell Quest software (BD Immunocytometry
systems). FACS Analysis was performed using FlowJo software
(Tree Star). For analysis, cells were gated in the following order:
single cells were gated based on fsc height vs. fsc area+ssc height
vs. ssc profiles, lymphocytes were gated on fsc and ssc profile,
residual dead cells were excluded by negative gating with v-amine
live/dead dye, and irrelevant non-B cells were excluded by
negative gating with dump markers.
Cell sorting and 59 Rapid Amplification of cDNA Ends (59
RACE)
For sorting of gp41 MPER tetramer-binding B cells, single cell
splenic suspensions were obtained from 5–10 naı ¨ve BALB/c 8 wk
females, pooled, and purified by negative depletion with CD43
MACS beads (Miltenyi Biotechnology). The resulting B cell
enriched fraction was stained as described in the flow cytometry
methods section and sorted into B220
+ CD19
+ gp41 MPER
+
fractions using a BDFACS Aria. Sorting gates for the gp41
MPER
+ fractions were set to include all events greater than
baseline staining without tetramer. Purity of sorted populations
was verified by a 1000-event post-sort step.
For 59 RACE analysis, gp41 MPER
+ fractions (or purified,
unsorted splenic B cells) were spun down and washed, immediately
after sorting. DNAse-free RNA was extracted and concentrated
using RNEasy Mini and Micro kits, respectively (Qiagen) and
quantitated using a NanoDrop ND-1000 spectrophotometer
(Fisher). cDNA was synthesized by oligo-dT priming using
SuperScript III (Invitrogen) and IgM-specific 59 RACE products
were amplified with the First Choice RLM-RACE PCR kit
(Ambion), using mouse HC ˜-specific primers in combination with
59 RACE primers, according to the manufacturer’s instructions.
PCR products were cloned into pGEM-T Easy vectors (Promega),
transformed in GC5 competent cells (CLP), and transformant
DNA was isolated, sequenced and analyzed in Ig Blast.
BCR internalization assays
Splenic B cells, purified by negative depletion with CD43
MACS beads, were pre-incubated on ice for 30 min with a 95:5
unlabeled/R-PE-labeled mixture of 10 mg/ml goat anti-mouse-
IgM+IgG (H+L) F(ab)2 fragments (Jackson ImmunoResearch
Laboratories). After washing, cells were resuspended in DMEM
10% FCS, and stimulated by warming to 37uC (or at 4uCa sa
control) for the indicated time points. Cells were fixed immediately
(for t=0) or at indicated time points with 1% methanol-free
formaldehyde PBS solution, stained with PerCP-B220 and either
APC-labeled gp41 MPER or scrambled gp41 MPER tetramers,
and detected by flow cytometry. Percent tetramer internalization
was calculated in gp41 MPER+B220+ subsets by the formula [%
gp41 MPER (To) -% gp41 MPER (Tn)]/%Sp62 (To) X 100. In
other experiments, cells were pre-incubated with 5 mg/ml
mannan, 125 mM a-methyl-mannopyranoside (Sigma-Aldrich),
or 10 mg/ml unlabeled goat anti-mouse-IgM+IgG (H+L) F(ab)2
fragments prior to staining with APC-labeled tetramers.
Microscopy of BCR cap formation
Purified naı ¨ve splenic B cells were incubated on ice for 30 min
with Alexa 488-labeled wheat germ agglutinin (Invitrogen) and
10 mg/ml R-PE-labeled goat anti-mouse IgM+IgG (H+L) F(ab)2
and APC-labeled gp41 MPER. After extensive washing, cells were
stimulated for indicated times. Images were acquired with a Nikon
TE2000-E2 inverted microscope employing a 40X magnification
lens from a CoolSNAPPHQ2 monochrome camera.
Intracellular staining
Splenocyte suspensions were incubated at 37uC for various
times with either APC-labeled F(ab)’2 anti-IgM (Jackson Immu-
noResearch) or APC-labeled gp41 MPER tetramers. Stimulations
were stopped by the addition of PhosFlow Lyse/Fix buffer (BD)
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FITC prior to permeabilization with PhosFlow Perm Buffer III
(BD). Permeabilized cells were stained with a PE-labeled Ab to
Erk1 and Erk2 (BD), according to the manufacturer’s instructions.
Cells were fixed with 2% paraformaldehyde, and all data were
collected and analyzed as done for standard flow cytometry.
Immunoblotting and phosphotyrosine analysis
5610
6 splenic BALB/c B cells were isolated by negative
depletion of CD43-expressing cells with anti-mouse CD43 MACS
beads (Miltenyi Biotech) to .95% purity, as assessed by flow
cytometry. Purified B cells were equilibrated to 37uCi na
humidified incubator and stimulated with gp41 MPER tetramers
or F(ab)’2 anti-IgM (Jackson ImmunoResearch) in 5% FBS-
containing DMEM media for various times. Whole cell extracts
were made by lysing cell pellets in 1% NP-40 lysis buffer
supplemented with PhosSTOP and complete, mini EDTA-free
protease inhibitor tablets (Roche) and insoluble cellular debris was
removed by centrifugation. Extracts were fractionated by reducing
SDS PAGE on Novex Bis-Tris Mini gels (Invitrogen) and
transferred to Invitrolon PVDF membranes (Invitrogen) using
the Xcell II blot module. Primary Abs used were anti-
phosphotyrosine clone 4G10 (Upstate) and anti-GAPDH (Milli-
pore). Secondary Abs used were goat-anti-mouse IgG1 or IgG2a,
both coupled to HRP (Jackson ImmunoResearch). Blots were
developed using the WesternLightning ECL system (Perkin
Elmer).
Production of IgM fragments and Surface Plasmon
Resonance (SPR)
2F5 was purchased from Polymun and the CD4-inducible anti-
HIV-1 mAb 17b was provided by Dr. J. Robinson. Purified mouse
pentameric IgM
a, BD clone G155-228 and IgM
b, BD clone C48-6
(both derived from J558 VH-expressing, TNP-KLH-specific mAb
cell lines) were fragmented into monomeric or F(ab)2 fragments
and purified using the IgM fragmentation kit (Pierce), according to
the manufacturer’s instructions. Purity of fragments was confirmed
by running fragments on non-reducing gels and staining with
Coomassie Blue. All SPR measurements of IgM fragment
interactions with the gp41 MPER epitope were conducted on a
BIAcore 3000 instrument, and data analyses, including affinity
measurements, were performed using the BIAevaluation 4.1
software (BIAcore), as previously described [31].
Supporting Information
Figure S1 Cross comparison of HIV-1 Env-specific B cell
tetramer binding to mAb-coated beads and mAb cell lines. A)
Beads coated with human mAbs 7B9 and F39F (specific to the HIV-
1 Env gp120 V3 loop, previously described in [8,77]), the human
mAb 7B2 (specific to the HIV-1 Env gp41 immunodominant (ID)
domain; kindly provided by James Robinson, Tulane University),
the human mAb A32 (specific to the the HIV-1 Env CD4 binding
site; previously described in [78]), and the human mAb 13H11 (a
non-neutralizing mAb specific to the HIV-1 Env gp41 MPER
epitope; previously described in [40]), respectively were either left
unstained (filled histograms) or stained with various HIV-1 Env-
specificB celltetramers(openhistograms).Note thatepitope-specific
mAbs only bound tetramers bearing the respective cognate epitope
and did bind tetramers with their respective epitopes scrambled.
P3X63/Ag8 (previously described in [77]) is a mAb lacking HIV-1
epitope specificity and was used as additional negative control for
tetramer binding. B) mAb hybridoma cell lines P3X63/Ag8, F39F,
7B2, and 13H11 were either left unstained (filled histograms) or
reacted with various HIV-1 Env-specific B cell tetramers (open
histograms). Surface immunoglobulin expression on cell lines was
demonstrated by staining with anti-mouse-IgG (P3X63/Ag8 and
13H11) or anti-human-IgG (F39F and 7B2) reagents.
Found at: doi:10.1371/journal.pone.0007215.s001 (1.62 MB EPS)
Figure S2 Surface plasmon resonance analysis of C57BL/6 and
BALB/c naı ¨ve serum reactivity to the gp41 MPER 2F5 epitope.
1:5 dilutions of serum from unimmunized 12 wk-old BALB/c and
C57BL/6 mice or 10 micrograms of purified 2F5 mAb (used as a
positive control) were captured over biotinylated gp41 MPER
peptide, anchored to an L1 sensor chip, as described in Materials
and Methods. Results are representative of two independent
experiments.
Found at: doi:10.1371/journal.pone.0007215.s002 (0.26 MB EPS)
Figure S3 Surface plasmon resonance analysis comparing IgMa
and IgMb binding to various gp41 MPER peptides. 10
micrograms of purified monomeric or F(ab)2 fragments derived
from TNP-KLH-specific IgMa and IgMb mAbs were injected
over the following biotinylated peptides: gp41 MPER (aka Sp62,
containing the 20 aa ‘‘optimal/higher affinity’’ gp41 MPER 2F5
epitope), scrambled gp41 MPER, gp41 MPER (gp120 Env642-
678; aka DP178Q16L, containing a ‘‘lower-affinity’’ gp41 MPER
2F5 epitope, comprised of 16 additional N-terminal residues of the
gp41 MPER HR-2 region), and gp41 HR1, a peptide spanning a
region of the gp41 MPER outside the 2F5 epitope. Results are
representative of two independent experiments.
Found at: doi:10.1371/journal.pone.0007215.s003 (0.33 MB EPS)
Figure S4 Surface plasmon resonance analysis of IgMa and
IgMb F(ab)2 fragment binding to TNP-BSA. 10 micrograms of
purified F(ab)2 fragments derived from the TNP-KLH-specific
IgMa and IgMb mAbs (BD clones G155-228 and C48-6,
respectively) were injected over a sensor chip immobilized with a
2,4,6-Trinitrophenyl hapten-Bovine Serum Albumin conjugate
(TNP-BSA, conjugation ratio 2 (T-5050-10), Biosearch Technol-
ogies Inc.). Results were subtracted from a sensor chip coated with
BSA alone, and mAb 13H11 (specific for gp41 MPER, but non-
reactive with TNP) was used as a negative control. Results are
representative of two independent experiments.
Found at: doi:10.1371/journal.pone.0007215.s004 (0.27 MB EPS)
Table S1
Found at: doi:10.1371/journal.pone.0007215.s005 (0.64 MB EPS)
Table S2
Found at: doi:10.1371/journal.pone.0007215.s006 (0.52 MB EPS)
Table S3
Found at: doi:10.1371/journal.pone.0007215.s007 (0.29 MB EPS)
Table S4
Found at: doi:10.1371/journal.pone.0007215.s008 (0.48 MB EPS)
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